Buscopan 10 mg Coated Tablets

  • Name:

    Buscopan 10 mg Coated Tablets

  • Company:
    info
  • Active Ingredients:

    hyoscine butylbromide

  • Legal Category:

    Supply through pharmacy only

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 24/10/18

files-icon(Click to Download)

XPIL

Summary of Product Characteristics last updated on medicines.ie: 18/12/2017
print

Print ViewKeyword Search SmPC

SANOFI

SANOFI

Company Products

Medicine NameActive Ingredients
Medicine Name Adenocor Active Ingredients Adenosine
Medicine Name Amaryl 1mg Tablets Active Ingredients Glimepiride
Medicine Name Amaryl 3mg Tablets Active Ingredients Glimepiride
Medicine Name Anthisan Cream Active Ingredients Mepyramine Maleate
Medicine Name Apidra 100 units/ml solution for injection in a cartridge Active Ingredients Insulin Glulisine
Medicine Name Apidra 100 Units/ml solution for injection in a vial Active Ingredients Insulin Glulisine
Medicine Name Apidra SoloStar 100 units/ml solution for injection in a pre-filled pen Active Ingredients Insulin Glulisine
Medicine Name Aprovel 150mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 300mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 75mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Arava 10 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Arava 20 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Arelix Tablets 6mg Active Ingredients Piretanide
Medicine Name Bisolvon Oral Solution Active Ingredients Bromhexine hydrochloride
Medicine Name Brolene 0.1%w/v Eye Drops Solution Active Ingredients Propamidine Isethionate
Medicine Name Brolene 0.15% w/w Eye Ointment Active Ingredients Dibromopropamidine Isethionate
Medicine Name Buscopan 10 mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Ampoules Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Rx 10mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Calcium Resonium Active Ingredients Calcium polystyrene sulfonate
Medicine Name Cerubidin 20mg Powder for Solution for Injection Active Ingredients daunorubicin hydrochloride
Medicine Name Cidomycin Paediatric 20mg/2ml Solution For Injection Active Ingredients Gentamicin sulfate
Medicine Name Claforan Powder for Solution for Injection 1g Active Ingredients Cefotaxime sodium
Medicine Name Claforan Powder for Solution for Injection 500mg Active Ingredients Cefotaxime sodium
Medicine Name Clexane 10,000 IU (100mg)/1ml Solution for Injection Active Ingredients Enoxaparin sodium
1 - 0 of 176 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 24 October 2018 PIL

Reasons for updating

  • XPIL Created

Updated on 18 December 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through pharmacy only

Updated on 18 December 2017 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4.3 - Contraindications

The sentence regarding hypersensitivity has been relocated from being the last bullet point to the first bullet point.
Two new bullet points have been added (mechanical stenosis in the gastrointestinal tract and paralytical or obstructive ileus).

Section 10 - Date of Revision of the Text

The date has been amended from August 2017 to December 2017.

Updated on 14 December 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 14 December 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 6 - date of revision

Updated on 15 August 2017 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 7 (Marketing Authorisation Holder) has been amended.  Boehringer Ingelheim Limited details have been replaced by sanofi-aventis Ireland Ltd details.

Section 8 (Marketing Authorisation Number) has been amended.  PA 7/16/1 has been replaced by PA 540/181/2.

Section 10 (Date of Revision of the Text) has been amended from October 2016 to August 2017.

Updated on 11 August 2017 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 24 March 2017 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text
  • Change to legal category

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

SPC updated following amendment of legal classification from POM to OTC.

The following changes have been made to enable it to be suitable for OTC supply:

Section 1 - Product name changed to Buscopan 10 mg Coated Tablets
Section 4.1 - Addition of a specific indication for Irritable Bowel Syndrome (IBS) with consequential dosage information added to section 4.2
Section 4.2 - Dosage in children under 12 years of age removed from SPC
Section 4.2 - Warning added about a 2 week treatment period
Section 4.3 - Addition of "10 mg Coated" and "are contraindicated in patients with:" text
Section 4.4 - Addition of warnings (in line with those already registered in the UK) required for OTC supply
Section 4.5 - Addition of "10 mg Coated Tablets" text
Section 4.6 - Addition of "butylbromide" text in Breastfeeding paragraph, addition of "10 mg Coated" text in Breastfeeding paragraph
Section 4.8 - Addition of "hyoscine butylbromide" text in first paragraph, addition of "10 mg Coated Tablets" text in first paragraph
Section 4.9 - Addition of "10 mg Coated Tablets" text in first paragraph of Therapy sub-heading, addition of "should be considered" in second paragraph of Therapy sub-heading
Section 5.1 - Addition of "Hyoscine butylbromide" text at beginning of second paragraph
Section 6.4 - Amendment to storage precautions
Section 6.5 - OTC pack sizes of 20s and 40s added and existing POM pack sizes deleted
Section 10 - Revision date updated from January 2015 to October 2016
Sections 2, 4.2, 4.3, 4.4, 4.6, 5.1 and 5.2 - Minor updates to align with current EU QRD SPC template

The updated SPC has been uploaded to medicines.ie to align with the OTC product launch date.

Updated on 22 March 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - use in children and adolescents
  • Change to section 3 - dose and frequency
  • Change to section 3 - use in children/adolescents
  • Change to section 3 - how to take/use
  • Change to section 3 - duration of treatment
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision
  • Change to name of medicinal product

Updated on 4 February 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4.8 Undesirable Effects

The Irish authority name and contact details have been updated in the adverse event reporting statements included in this section following the change from IMB to HPRA.

 

Section 10 Date of Revision of the Text

The date has been amended from December 2013 to January 2015.

 

Updated on 3 February 2015 PIL

Reasons for updating

  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 19 December 2013 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4.8 Undesirable Effects

New text regarding the reporting of suspected adverse reactions has been added at the end of this section.  In total, two new paragraphs have been added.

 

Section 10 Date of Revision of the Text

The date has been amended from October 2011 to December 2013.

Updated on 17 December 2013 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 19 November 2012 PIL

Reasons for updating

  • Change of manufacturer
  • Change to date of revision

Updated on 2 November 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision
  • Change to dosage and administration

Updated on 25 October 2011 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4 has been updated to include additional information.
Section 5.1 additional statement has been added.
Section 5.2 has been re-written.
Section 10 has been updated.

Updated on 29 January 2010 PIL

Reasons for updating

  • Change of manufacturer

Updated on 26 November 2009 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 2 - Qualitative and Quantitative Composition

Previous wording: For excipients, see 6.1.

Updated wording:  

 

 

Excipients: Contains Sucrose 41.2 mg.

 

            For a full list of excipients, see section 6.1.

 

 

Section 4.2 – Posology and method of administration


Minor formatting change.

 

Section 9 – Date of Renewal of the Authorisation

 

1 April 2009

 

Section 10: Date of revision of the text

 

October 2009

 

 

Updated on 19 September 2008 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 26 August 2008 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.1 - List of excipients
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

 The main changes are administrative in nature.  

Section 4.5 Interaction with other medicinal products and other forms of interaction

The previous SPC stated that the anticholinergic effect of some drugs may be intensified with Buscopan.  The list of drugs now includes other anticholinergics (e.g. tiotropium, ipratropium).

Updated on 18 August 2006 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 1 August 2006 SmPC

Reasons for updating

  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 5.1 (List of Excipients) has been updated to include the E-number for titanium dioxide.
Other small formatting changes throughout document.

Updated on 15 May 2006 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 3 May 2006 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Supply through pharmacy only

Updated on 13 April 2006 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Updated on 22 October 2004 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Updated on 17 September 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 9 June 2004 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration

Legal category: Supply through pharmacy only

Updated on 3 June 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Supply through pharmacy only